Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:2-amino-2-deoxy-D-galactopyranose
go back to main search page
Accession:CHEBI:60312 term browser browse the term
Definition:The pyranose form of D-galactosamine.
Synonyms:related_synonym: 2-Amino-2-deoxy-D-galactose;   Chondrosamine;   D-2-Amino-2-deoxygalactose;   D-Chondrosamine;   D-GalN;   D-Galactosamine;   Formula=C6H13NO5;   Galactosamine;   InChI=1S/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4+,5-,6?/m1/s1;   InChIKey=MSWZFWKMSRAUBD-GASJEMHNSA-N;   SMILES=N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O
 xref: Beilstein:2042269;   CAS:7535-00-4;   KEGG:C02262
 xref_mesh: MESH:D005688
 xref: PMID:17456244;   PMID:19913595;   PMID:28709622;   PMID:28752362;   PMID:28821814;   PMID:28921968;   Reaxys:2042269
 cyclic_relationship: is_conjugate_base_of CHEBI:144817


show annotations for term's descendants           Sort by:
2-amino-2-deoxy-D-galactopyranose term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ache acetylcholinesterase increases activity
multiple interactions		 ISO Galactosamine results in increased activity of ACHE protein
Vitamin U inhibits the reaction [Galactosamine results in increased activity of ACHE protein]		 CTD PMID:35673974 NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728 		JBrowse link
G Acta2 actin alpha 2, smooth muscle, aorta increases expression
multiple interactions		 ISO Galactosamine results in increased expression of ACTA2 mRNA; Galactosamine results in increased expression of ACTA2 protein
Genistein inhibits the reaction [Galactosamine results in increased expression of ACTA2 mRNA]; Genistein inhibits the reaction [Galactosamine results in increased expression of ACTA2 protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of ACTA2 protein]		 CTD PMID:27836788 PMID:27876602 NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990 		JBrowse link
G Actb actin, beta increases expression ISO Galactosamine results in increased expression of ACTB mRNA CTD PMID:22563491 NCBI chr 5:142,888,870...142,892,509
Ensembl chr 5:142,888,870...142,892,509 		JBrowse link
G Afp alpha fetoprotein increases expression ISO Galactosamine results in increased expression of AFP protein CTD PMID:61145 PMID:16965562 NCBI chr 5:90,638,573...90,656,766
Ensembl chr 5:90,638,596...90,656,766 		JBrowse link
G Alb albumin multiple interactions
increases expression
decreases expression		 ISO [ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of IL10 protein; [ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased expression of ALB protein; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased expression of ALB protein]
Galactosamine results in increased expression of ALB mRNA
Galactosamine results in decreased expression of ALB protein		 CTD PMID:17963606 PMID:18779383 PMID:22310181 PMID:35838105 NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461 		JBrowse link
G Ambp alpha 1 microglobulin/bikunin precursor increases expression ISO Galactosamine results in increased expression of AMBP mRNA CTD PMID:18779383 NCBI chr 4:63,061,512...63,072,409
Ensembl chr 4:63,061,512...63,073,036 		JBrowse link
G Apoe apolipoprotein E decreases expression ISO Galactosamine results in decreased expression of APOE protein CTD PMID:6631239 NCBI chr 7:19,430,169...19,434,326
Ensembl chr 7:19,430,034...19,433,113 		JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 protein CTD PMID:28844859 NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742 		JBrowse link
G Atm ataxia telangiectasia mutated increases expression
multiple interactions		 ISO Galactosamine results in increased expression of ATM protein
glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of ATM protein]		 CTD PMID:24565947 NCBI chr 9:53,348,422...53,448,125
Ensembl chr 9:53,350,449...53,448,040 		JBrowse link
G Bax BCL2-associated X protein multiple interactions
increases expression		 EXP
ISO		 [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form]
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX mRNA; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of BAX mRNA]
Galactosamine results in increased expression of BAX mRNA; Galactosamine results in increased expression of BAX protein		 CTD PMID:20558151 PMID:20850421 PMID:21401295 PMID:22118634 PMID:24565947 NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322 		JBrowse link
G Bcl2 B cell leukemia/lymphoma 2 multiple interactions
decreases expression		 EXP
ISO		 [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of BCL2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of BCL2 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form]
Galactosamine results in decreased expression of BCL2 mRNA; Galactosamine results in decreased expression of BCL2 protein
glycine propionyl carnitine inhibits the reaction [Galactosamine results in decreased expression of BCL2 mRNA]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of BCL2 protein]		 CTD PMID:20558151 PMID:20850421 PMID:22118634 PMID:24565947 NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004 		JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BID mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of BID protein CTD PMID:12907702 PMID:21401295 NCBI chr 6:120,870,080...120,894,074
Ensembl chr 6:120,868,891...120,893,814 		JBrowse link
G Casp1 caspase 1 multiple interactions EXP [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP1 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP1 protein] CTD PMID:32453893 NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290 		JBrowse link
G Casp3 caspase 3 multiple interactions
increases activity
increases expression		 EXP
ISO		 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP3 protein]; [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein; [Galactosamine co-treated with Endotoxins] results in increased activity of CASP3 protein; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP3 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; [Nitric Oxide Donors results in increased abundance of Nitric Oxide] inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]; [TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form]; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein]; Biliverdine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]]; Dithiothreitol inhibits the reaction [Nitric Oxide Donors inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]]; gentiopicroside inhibits the reaction [[[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein modified form]; Melatonin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein]; Methylene Chloride inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP3 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form]; TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein]
2-Acetylaminofluorene inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of CASP3 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of CASP3 protein; Alprostadil inhibits the reaction [Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein]; Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of CASP3 mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of CASP3 protein]
Galactosamine results in increased expression of CASP3 mRNA; Galactosamine results in increased expression of CASP3 protein
[Galactosamine co-treated with TNF protein] results in increased activity of CASP3 protein; alpha-Tocopherol inhibits the reaction [Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein]; Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein; Ketoconazole inhibits the reaction [Galactosamine results in increased activity of CASP3 protein]; Rifampin promotes the reaction [Galactosamine results in increased activity of CASP3 protein]		 CTD PMID:9388267 PMID:12907702 PMID:14512878 PMID:15486963 PMID:15565661 More... NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724 		JBrowse link
G Casp7 caspase 7 multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP7 protein; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP7 protein] CTD PMID:21146893 NCBI chr19:56,382,640...56,430,780
Ensembl chr19:56,385,561...56,430,776 		JBrowse link
G Casp8 caspase 8 multiple interactions EXP 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP8 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP8 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP8 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP8 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP8 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP8 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP8 protein modified form]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP8 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP8 protein] CTD PMID:20558151 PMID:20850421 PMID:21146893 PMID:24830863 PMID:31332890 NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662 		JBrowse link
G Casp9 caspase 9 multiple interactions
increases expression		 EXP
ISO		 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP9 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP9 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP9 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP9 protein; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP9 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP9 protein modified form]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP9 protein]
Galactosamine results in increased expression of CASP9 protein
mangiferin inhibits the reaction [Galactosamine results in increased expression of CASP9 protein]		 CTD PMID:20558151 PMID:22118634 PMID:24830863 PMID:31332890 NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287 		JBrowse link
G Cat catalase multiple interactions
decreases activity
increases activity		 EXP
ISO		 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased activity of CAT protein]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; [Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased activity of CAT protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Caffeine inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Oligopeptides inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]]
Galactosamine results in decreased activity of CAT protein
[Ascorbic Acid co-treated with beta Carotene co-treated with alpha-Tocopherol co-treated with Sodium Selenite] inhibits the reaction [Galactosamine results in increased activity of CAT protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of CAT protein; glycine propionyl carnitine inhibits the reaction [Galactosamine results in decreased activity of CAT protein]; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of CAT protein]; Vitamin U inhibits the reaction [Galactosamine results in decreased activity of CAT protein]		 CTD PMID:19153979 PMID:22154906 PMID:27836788 PMID:30236599 PMID:31022331 More... NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions EXP 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CCL2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CCL2 mRNA]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]] CTD PMID:21146893 PMID:28887131 PMID:35691465 NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279 		JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein] CTD PMID:21146893 NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344 		JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein; Indomethacin promotes the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein]; nimesulide promotes the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein] CTD PMID:22107987 NCBI chr 7:34,818,718...34,821,353
Ensembl chr 7:34,818,718...34,821,353 		JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein; baicalein inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein]; Silymarin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein] CTD PMID:20850421 NCBI chr 1:58,750,353...58,798,043
Ensembl chr 1:58,750,667...58,798,043 		JBrowse link
G Chuk conserved helix-loop-helix ubiquitous kinase increases phosphorylation
multiple interactions		 ISO Galactosamine results in increased phosphorylation of CHUK protein
mangiferin inhibits the reaction [Galactosamine results in increased phosphorylation of CHUK protein]		 CTD PMID:22310181 NCBI chr19:44,061,773...44,095,940
Ensembl chr19:44,061,774...44,095,919 		JBrowse link
G Col1a1 collagen, type I, alpha 1 increases expression
multiple interactions		 ISO Galactosamine results in increased expression of COL1A1 mRNA
Genistein inhibits the reaction [Galactosamine results in increased expression of COL1A1 mRNA]		 CTD PMID:27876602 NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868 		JBrowse link
G Col3a1 collagen, type III, alpha 1 increases expression
multiple interactions		 ISO Galactosamine results in increased expression of COL3A1 mRNA
Genistein inhibits the reaction [Galactosamine results in increased expression of COL3A1 mRNA]		 CTD PMID:27876602 NCBI chr 1:45,350,698...45,388,866
Ensembl chr 1:45,350,698...45,388,866 		JBrowse link
G Cpt1a carnitine palmitoyltransferase 1a, liver multiple interactions
decreases expression		 ISO alpha-Tocopherol inhibits the reaction [Galactosamine results in decreased expression of CPT1A mRNA] CTD PMID:17936189 NCBI chr19:3,372,328...3,435,735
Ensembl chr19:3,372,334...3,435,733 		JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions EXP [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL2 mRNA; [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL2 protein CTD PMID:15576625 NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797 		JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions EXP [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL1 mRNA; [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL1 protein CTD PMID:15576625 NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459 		JBrowse link
G Cyba cytochrome b-245, alpha polypeptide multiple interactions EXP [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CYBA protein; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CYBA protein] CTD PMID:28887131 NCBI chr 8:123,151,510...123,159,679
Ensembl chr 8:123,151,515...123,159,669 		JBrowse link
G Cycs cytochrome c, somatic multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in increased localization of CYCS protein; [Lipopolysaccharides co-treated with Galactosamine] affects the localization of CYCS protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of CYCS protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased localization of CYCS protein] CTD PMID:20558151 PMID:20850421 NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 decreases expression ISO Galactosamine results in decreased expression of CYP1A2 protein CTD PMID:16208626 NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 decreases expression
multiple interactions		 ISO Galactosamine results in decreased expression of CYP2E1 protein
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of CYP2E1 protein; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of CYP2E1 protein]		 CTD PMID:16208626 PMID:35838105 NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of DDIT3 mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of DDIT3 mRNA CTD PMID:28844859 NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157 		JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2, subunit 1 alpha multiple interactions ISO 4-phenylbutyric acid affects the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased phosphorylation of EIF2S1 protein]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of EIF2S1 mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of and results in decreased phosphorylation of EIF2S1 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of EIF2S1 mRNA CTD PMID:28844859 NCBI chr12:78,908,846...78,933,784
Ensembl chr12:78,908,593...78,933,784 		JBrowse link
G G6pdx glucose-6-phosphate dehydrogenase X-linked multiple interactions ISO [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of G6PD protein; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of G6PD protein] CTD PMID:35838105 NCBI chr  X:73,453,089...73,472,486
Ensembl chr  X:73,453,089...73,472,800 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions EXP 8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLC mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLC mRNA; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLC mRNA] CTD PMID:35691465 NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767 		JBrowse link
G Gclm glutamate-cysteine ligase, modifier subunit multiple interactions EXP 8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLM mRNA]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GCLM mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLM mRNA; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLM mRNA] CTD PMID:28887131 PMID:35691465 NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381 		JBrowse link
G Gpt glutamic pyruvic transaminase, soluble multiple interactions
increases expression		 ISO
EXP		 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of GPT protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein; Genistein inhibits the reaction [Galactosamine results in increased expression of GPT protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of GPT protein]; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of GPT protein]
(2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]]; (2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]]; 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]; 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein; [Galactosamine co-treated with Lipopolysaccharides] promotes the reaction [idelalisib results in increased expression of ALT protein]; [Galactosamine co-treated with Lipopolysaccharides] promotes the reaction [Miransertib results in increased expression of ALT protein]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of GPT protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of GPT protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein; Acetylcysteine inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of GPT protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; Plant Extracts inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of GPT protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein]; stattic inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]		 CTD PMID:19153979 PMID:24565947 PMID:24830863 PMID:25620059 PMID:27876602 More... NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886 		JBrowse link
G Gsr glutathione reductase multiple interactions
decreases activity		 ISO [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of GSR protein; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of GSR protein]; Vitamin U inhibits the reaction [Galactosamine results in decreased activity of GSR protein] CTD PMID:35673974 PMID:35838105 NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191 		JBrowse link
G H3f4 H3.4 histone, cluster member increases expression ISO Galactosamine results in increased expression of H3F4 mRNA CTD PMID:11779202 NCBI chr11:58,852,537...58,853,099
Ensembl chr11:58,852,599...58,853,364 		JBrowse link
G Habp2 hyaluronic acid binding protein 2 increases activity EXP Galactosamine results in increased activity of HABP2 protein CTD PMID:11510480 NCBI chr19:56,275,541...56,309,252
Ensembl chr19:56,275,569...56,309,254 		JBrowse link
G Hbegf heparin-binding EGF-like growth factor multiple interactions EXP [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA] CTD PMID:28887131 NCBI chr18:36,637,980...36,648,858
Ensembl chr18:36,637,980...36,648,858 		JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF protein]; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF protein CTD PMID:28844859 NCBI chr 5:16,758,493...16,827,448
Ensembl chr 5:16,758,493...16,825,150 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
decreases expression		 EXP
ISO		 8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]; 8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein; Galactosamine inhibits the reaction [cobaltiprotoporphyrin results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]]
[[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HMOX1 mRNA] which results in increased chemical synthesis of Bilirubin; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HMOX1 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of HMOX1 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA; mangiferin inhibits the reaction [Galactosamine results in decreased expression of HMOX1 protein]; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of HMOX1 protein]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]		 CTD PMID:14512878 PMID:19796704 PMID:21401295 PMID:22310181 PMID:35691465 More... NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217 		JBrowse link
G Hspa5 heat shock protein 5 multiple interactions ISO 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 protein CTD PMID:28844859 NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559 		JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO Galactosamine analog inhibits the reaction [TNF results in increased expression of ICAM1 protein] CTD PMID:16431966 NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113 		JBrowse link
G Ifng interferon gamma multiple interactions
increases expression		 EXP
ISO		 [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG mRNA]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein]
Galactosamine results in increased expression of IFNG mRNA
mangiferin inhibits the reaction [Galactosamine results in increased expression of IFNG mRNA]		 CTD PMID:15486963 PMID:22310181 NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797 		JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 increases expression ISO Galactosamine results in increased expression of IGFBP1 mRNA CTD PMID:11779202 NCBI chr11:7,147,787...7,152,546
Ensembl chr11:7,147,782...7,152,546 		JBrowse link
G Ikbkb inhibitor of kappaB kinase beta multiple interactions
increases phosphorylation		 ISO mangiferin inhibits the reaction [Galactosamine results in increased phosphorylation of IKBKB protein] CTD PMID:22310181 NCBI chr 8:23,149,228...23,196,605
Ensembl chr 8:23,149,228...23,196,605 		JBrowse link
G Il10 interleukin 10 multiple interactions
decreases expression		 EXP
ISO		 [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein]
[ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of IL10 protein; mangiferin inhibits the reaction [Galactosamine results in decreased expression of IL10 mRNA]		 CTD PMID:15486963 PMID:17963606 PMID:22310181 NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711 		JBrowse link
G Il12b interleukin 12b multiple interactions
increases expression		 EXP
ISO		 [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA
Galactosamine results in increased expression of IL12B mRNA
mangiferin inhibits the reaction [Galactosamine results in increased expression of IL12B mRNA]		 CTD PMID:19913045 PMID:22310181 NCBI chr11:44,290,890...44,305,504
Ensembl chr11:44,290,890...44,304,860 		JBrowse link
G Il18 interleukin 18 increases expression
multiple interactions		 EXP
ISO		 Galactosamine results in increased expression of IL18 mRNA; Galactosamine results in increased expression of IL18 protein
[LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; Plant Preparations inhibits the reaction [Galactosamine results in increased expression of IL18 mRNA]; Plant Preparations inhibits the reaction [Galactosamine results in increased expression of IL18 protein]
mangiferin inhibits the reaction [Galactosamine results in increased expression of IL18 mRNA]		 CTD PMID:19913045 PMID:20102673 PMID:22310181 NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140 		JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases expression		 ISO
EXP		 Genistein inhibits the reaction [Galactosamine results in increased expression of IL1B mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of IL1B mRNA]
2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein]]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA; [Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; nilotinib inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IL1B protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]]		 CTD PMID:15135310 PMID:22310181 PMID:25620059 PMID:28125915 PMID:28887131 More... NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059 		JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression		 EXP
ISO		 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]]
glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of IL6 mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of IL6 mRNA]		 CTD PMID:15135310 PMID:15486963 PMID:22310181 PMID:24830863 PMID:27836788 More... NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979 		JBrowse link
G Irak1 interleukin-1 receptor-associated kinase 1 multiple interactions EXP [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of IRAK1 protein; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]] CTD PMID:28213090 NCBI chr  X:73,057,520...73,067,527
Ensembl chr  X:73,057,520...73,067,524 		JBrowse link
G Keap1 kelch-like ECH-associated protein 1 multiple interactions EXP 8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased degradation of KEAP1 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased degradation of KEAP1 protein; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased degradation of KEAP1 protein]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased degradation of KEAP1 protein] CTD PMID:35691465 NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657 		JBrowse link
G Lcat lecithin cholesterol acyltransferase decreases activity ISO Galactosamine results in decreased activity of LCAT protein CTD PMID:6631239 NCBI chr 8:106,666,183...106,670,034
Ensembl chr 8:106,666,183...106,670,014 		JBrowse link
G Lep leptin multiple interactions
increases response to substance		 EXP [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEP gene mutant form results in increased susceptibility to Galactosamine] CTD PMID:19913045 NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876 		JBrowse link
G Lepr leptin receptor multiple interactions
increases response to substance		 EXP [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEPR gene mutant form results in increased susceptibility to Galactosamine] CTD PMID:19913045 NCBI chr 4:101,574,393...101,676,375
Ensembl chr 4:101,574,601...101,672,549 		JBrowse link
G Mapk1 mitogen-activated protein kinase 1 multiple interactions
increases phosphorylation		 EXP
ISO		 [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased phosphorylation of MAPK1 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK1 protein modified form; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK1 protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form]
Galactosamine results in increased phosphorylation of MAPK1 protein
Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of MAPK1 protein]		 CTD PMID:20558151 PMID:20850421 PMID:25620059 PMID:28887131 NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317 		JBrowse link
G Mapk3 mitogen-activated protein kinase 3 multiple interactions
increases phosphorylation		 EXP
ISO		 [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased phosphorylation of MAPK3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK3 protein modified form; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK3 protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form]
Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of MAPK3 protein]		 CTD PMID:20558151 PMID:20850421 PMID:25620059 PMID:28887131 NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991 		JBrowse link
G Met met proto-oncogene multiple interactions EXP
ISO		 [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of MET mRNA
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of MET mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of MET mRNA		 CTD PMID:28844859 PMID:28887131 NCBI chr 6:17,463,351...17,573,979
Ensembl chr 6:17,463,799...17,573,979 		JBrowse link
G Mpo myeloperoxidase multiple interactions
increases activity		 EXP
ISO		 (2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein]]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of MPO protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of MPO protein]
[Ascorbic Acid co-treated with beta Carotene co-treated with alpha-Tocopherol co-treated with Sodium Selenite] inhibits the reaction [Galactosamine results in increased activity of MPO protein]; Vitamin U inhibits the reaction [Galactosamine results in increased activity of MPO protein]		 CTD PMID:28887131 PMID:30550845 PMID:31022331 PMID:32453893 PMID:35673974 NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239 		JBrowse link
G Ndufb6 NADH:ubiquinone oxidoreductase subunit B6 multiple interactions
decreases expression		 ISO Acetylcysteine inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA]; coenzyme Q10 inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA] CTD PMID:19523936 NCBI chr 4:40,270,591...40,279,421
Ensembl chr 4:40,270,591...40,279,421 		JBrowse link
G Nfe2l2 nuclear factor, erythroid derived 2, like 2 affects localization
decreases expression
multiple interactions
increases activity		 ISO
EXP		 Galactosamine affects the localization of NFE2L2 protein
Galactosamine results in decreased expression of NFE2L2 protein
mangiferin affects the reaction [Galactosamine affects the localization of NFE2L2 protein]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of NFE2L2 protein]
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA]; Plant Extracts promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA]; Plant Extracts promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein]
Galactosamine results in increased activity of NFE2L2 protein		 CTD PMID:22310181 PMID:28887131 PMID:30114225 PMID:30203046 PMID:30236599 NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985 		JBrowse link
G Nfkb1 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 multiple interactions ISO alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [NFKB1 protein binds to NFKB1 protein]]; alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]]; Galactosamine results in increased activity of [NFKB1 protein binds to NFKB1 protein]; Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein] CTD PMID:17936189 NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308 		JBrowse link
G Nfkbia nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha multiple interactions
decreases expression		 ISO
EXP		 Alprostadil inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]; Enzyme Inhibitors inhibits the reaction [Alprostadil inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]
[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA protein modified form; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA protein modified form]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein]		 CTD PMID:15565661 PMID:20850421 PMID:22310181 PMID:28213090 PMID:30550845 NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432 		JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions EXP [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NLRP3 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NLRP3 protein] CTD PMID:32453893 NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782 		JBrowse link
G Nos2 nitric oxide synthase 2, inducible multiple interactions
increases expression		 EXP
ISO		 [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein]
[[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitrites; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NOS2 mRNA; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 mRNA]; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 promoter]; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; Enzyme Inhibitors inhibits the reaction [Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]]; Galactosamine promotes the reaction [Alprostadil results in increased expression of NOS2 protein]; Genistein inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; mangiferin inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NOS2 mRNA]
Galactosamine results in increased expression of NOS2 mRNA; Galactosamine results in increased expression of NOS2 promoter; Galactosamine results in increased expression of NOS2 protein
alpha-Tocopherol inhibits the reaction [Galactosamine results in increased expression of NOS2 mRNA]		 CTD PMID:15189274 PMID:15565661 PMID:17936189 PMID:19796704 PMID:21401295 More... NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080 		JBrowse link
G Nqo1 NAD(P)H dehydrogenase, quinone 1 decreases expression
multiple interactions		 ISO
EXP		 Galactosamine results in decreased expression of NQO1 protein
mangiferin inhibits the reaction [Galactosamine results in decreased expression of NQO1 protein]
8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NQO1 protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NQO1 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NQO1 protein; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NQO1 protein]		 CTD PMID:22310181 PMID:28887131 PMID:35691465 NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase family, member 1 multiple interactions EXP [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein; gentiopicroside inhibits the reaction [[[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein] CTD PMID:20558151 NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha increases expression
decreases expression
multiple interactions
increases activity		 EXP
ISO		 Galactosamine results in increased expression of PPARA mRNA
Galactosamine results in decreased expression of PPARA mRNA
alpha-Tocopherol inhibits the reaction [Galactosamine results in decreased expression of PPARA mRNA]
Galactosamine results in increased activity of PPARA protein
[Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA mRNA; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA protein; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA mRNA; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA protein		 CTD PMID:17936189 PMID:25689681 PMID:30203046 PMID:30236599 NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020 		JBrowse link
G Pparg peroxisome proliferator activated receptor gamma multiple interactions EXP [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG protein; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG mRNA; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG protein; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG mRNA; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG protein; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG protein] CTD PMID:30236599 PMID:30550845 NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360 		JBrowse link
G Ppia peptidylprolyl isomerase A decreases expression ISO Galactosamine results in decreased expression of CYCA mRNA CTD PMID:22563491 NCBI chr11:6,365,867...6,369,817
Ensembl chr11:6,365,443...6,369,817 		JBrowse link
G Ptgs1 prostaglandin-endoperoxide synthase 1 multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA] CTD PMID:22107987 NCBI chr 2:36,106,758...36,142,287
Ensembl chr 2:36,120,438...36,142,284 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
increases expression		 EXP
ISO		 [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PTGS2 protein; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PTGS2 protein]
Galactosamine results in increased expression of PTGS2 protein
Genistein inhibits the reaction [Galactosamine results in increased expression of PTGS2 protein]		 CTD PMID:22107987 PMID:25620059 PMID:32453893 NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978 		JBrowse link
G Ptn pleiotrophin increases expression ISO Galactosamine results in increased expression of PTN mRNA; Galactosamine results in increased expression of PTN protein CTD PMID:12057922 NCBI chr 6:36,691,863...36,787,114
Ensembl chr 6:36,691,864...36,787,155 		JBrowse link
G Pttg1 pituitary tumor-transforming gene 1 affects response to substance ISO PTTG1 mRNA affects the susceptibility to Galactosamine CTD PMID:19800905 NCBI chr11:43,311,097...43,317,417
Ensembl chr11:43,311,077...43,317,078 		JBrowse link
G Rela v-rel reticuloendotheliosis viral oncogene homolog A (avian) multiple interactions
increases expression		 EXP
ISO		 [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA protein modified form; [Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein]
Galactosamine results in increased expression of RELA protein
mangiferin inhibits the reaction [Galactosamine results in increased expression of RELA protein]
alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]]; Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]		 CTD PMID:17936189 PMID:20850421 PMID:22310181 PMID:30550845 NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158 		JBrowse link
G Sdc3 syndecan 3 increases expression ISO Galactosamine results in increased expression of SDC3 mRNA CTD PMID:12057922 NCBI chr 4:130,519,855...130,553,629
Ensembl chr 4:130,519,848...130,553,630 		JBrowse link
G Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 increases expression ISO Galactosamine results in increased expression of SERPINE1 mRNA CTD PMID:11779202 NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122 		JBrowse link
G Sesn2 sestrin 2 multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of SESN2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of SESN2 protein CTD PMID:25637945 NCBI chr 4:132,220,115...132,237,767
Ensembl chr 4:132,219,343...132,237,812 		JBrowse link
G Smad2 SMAD family member 2 increases phosphorylation
multiple interactions		 ISO Galactosamine results in increased phosphorylation of SMAD2 protein
Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of SMAD2 protein]		 CTD PMID:27876602 NCBI chr18:76,369,898...76,444,819
Ensembl chr18:76,374,651...76,444,034 		JBrowse link
G Smad3 SMAD family member 3 increases phosphorylation
multiple interactions		 ISO Galactosamine results in increased phosphorylation of SMAD3 protein
Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of SMAD3 protein]		 CTD PMID:27876602 NCBI chr 9:63,554,048...63,665,276
Ensembl chr 9:63,554,049...63,665,276 		JBrowse link
G Smad7 SMAD family member 7 decreases expression
multiple interactions		 ISO Galactosamine results in decreased expression of SMAD7 protein
Genistein inhibits the reaction [Galactosamine results in decreased expression of SMAD7 protein]		 CTD PMID:27876602 NCBI chr18:75,500,436...75,529,006
Ensembl chr18:75,500,600...75,529,006 		JBrowse link
G Sod1 superoxide dismutase 1, soluble multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of SOD1 mRNA CTD PMID:21401295 NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217 		JBrowse link
G Sord sorbitol dehydrogenase multiple interactions EXP [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of SORD protein; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of SORD protein] CTD PMID:30822415 NCBI chr 2:122,065,320...122,095,818
Ensembl chr 2:122,065,230...122,095,821 		JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions EXP [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 protein]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEP gene mutant form results in increased susceptibility to Galactosamine]; SPP1 promotes the reaction [LEPR gene mutant form results in increased susceptibility to Galactosamine] CTD PMID:19913045 NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions EXP [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein] CTD PMID:28887131 NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366 		JBrowse link
G Stat5b signal transducer and activator of transcription 5B decreases activity EXP Galactosamine results in decreased activity of STAT5B protein CTD PMID:30114225 NCBI chr11:100,671,557...100,741,407
Ensembl chr11:100,671,557...100,741,550 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
increases expression		 ISO Genistein inhibits the reaction [Galactosamine results in increased expression of TGFB1 mRNA]; Genistein inhibits the reaction [Galactosamine results in increased expression of TGFB1 protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TGFB1 protein]
Galactosamine results in increased expression of TGFB1 mRNA; Galactosamine results in increased expression of TGFB1 protein		 CTD PMID:27836788 PMID:27876602 NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502 		JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions EXP [Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TLR4 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TLR4 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TLR4 protein] CTD PMID:28125915 PMID:32453893 NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521 		JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases expression		 EXP
ISO		 2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]]; 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA; [Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; [Nitric Oxide Donors results in increased abundance of Nitric Oxide] inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]; [TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]]; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF protein]; Dithiothreitol inhibits the reaction [Nitric Oxide Donors inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; hydroquinone metabolite inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein]; nilotinib inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; Prednisolone inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF mRNA]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]]
[ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of TNF protein; Alprostadil promotes the reaction [Galactosamine results in increased expression of TNF protein]; Genistein inhibits the reaction [Galactosamine results in increased expression of TNF protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TNF mRNA]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TNF protein]; mangiferin inhibits the reaction [Galactosamine results in increased expression of TNF mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of TNF protein]
[Galactosamine co-treated with TNF protein] results in increased activity of CASP3 protein; Galactosamine analog inhibits the reaction [TNF results in increased expression of ICAM1 protein]
Galactosamine results in increased expression of TNF mRNA; Galactosamine results in increased expression of TNF protein		 CTD PMID:9388267 PMID:10221824 PMID:11779202 PMID:14512878 PMID:15135310 More... NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983 		JBrowse link
G Traf6 TNF receptor-associated factor 6 multiple interactions EXP [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]] CTD PMID:28213090 NCBI chr 2:101,508,765...101,532,013
Ensembl chr 2:101,508,774...101,532,014 		JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of VEGFA mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of VEGFA mRNA CTD PMID:28844859 NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295 		JBrowse link
G Xdh xanthine dehydrogenase increases activity
multiple interactions		 ISO Galactosamine results in increased activity of XDH protein
Vitamin U inhibits the reaction [Galactosamine results in increased activity of XDH protein]		 CTD PMID:35673974 NCBI chr17:74,190,890...74,257,191
Ensembl chr17:74,190,890...74,257,191 		JBrowse link
G Xiap X-linked inhibitor of apoptosis multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein; baicalein inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein]; Silymarin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein] CTD PMID:20850421 NCBI chr  X:41,148,483...41,198,541
Ensembl chr  X:41,148,556...41,198,533 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 22182
    role 22167
      biological role 22166
        poison 19424
          toxin 16250
            2-amino-2-deoxy-D-galactopyranose 97
              alpha-D-galactosamine + 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 22182
    subatomic particle 22174
      composite particle 22174
        hadron 22174
          baryon 22174
            nucleon 22174
              atomic nucleus 22174
                atom 22174
                  main group element atom 22108
                    p-block element atom 22108
                      carbon group element atom 21909
                        carbon atom 21835
                          organic molecular entity 21835
                            heteroorganic entity 21490
                              organochalcogen compound 20980
                                organooxygen compound 20821
                                  carbohydrates and carbohydrate derivatives 16029
                                    carbohydrate 16029
                                      carbohydrate derivative 14779
                                        amino sugar 1479
                                          amino monosaccharide 1474
                                            hexosamine 1474
                                              galactosamine 97
                                                D-galactosamine 97
                                                  2-amino-2-deoxy-D-galactopyranose 97
                                                    alpha-D-galactosamine + 0
paths to the root